Menu
Recruiting NCT04654208

Swedish Ibrance Registries Insights (SIRI)

— Observational Malignant Neoplasm of Breast

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: palbociclib.
Who it may be relevant to
Registry conditions: Malignant Neoplasm of Breast. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Sweden
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)

Overview

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

Interventions

  • Drug palbociclib
    patients on palbociclib combination treatment

Primary outcome measures

  • Proportion of patients on treatment [Time frame: 01 January 2017 until 30 September 2020]
Secondary outcome measures (2)
  • Proportion of patients alive [Time frame: 01 January 2017 until 30 September 2020]
  • Describe the demographic and clinical characteristics of the patient population receiving palbociclib combination treatment [Time frame: 01 January 2017 until 30 September 2020]

Eligibility criteria

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  • One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
  • Age ≥18 years at index date

Exclusion criteria

There are no exclusion criteria

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Sweden · 1 center
  • Pfizer Sweden — Sollentuna

Identifiers

NCT: NCT04654208 · A5481158 · SIRI

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗